IDEXX Laboratories, Inc. (IDXX) EV/Sales Ratio: 10.38x
Is IDEXX Laboratories, Inc.’s EV/Sales ratio high or low?
IDEXX Laboratories, Inc.'s EV/Sales ratio of 10.38x is 16% below its 5-year average of 12.37x, near the low end of its 5-year range (7.83x–21.64x).
As of Sunday, June 14, 2026. 15.83% below its 12-month average of 12.33x.
IDXX EV/Sales Ratio Chart
IDXX Average EV/Sales Ratio Chart
IDXX Current vs Average EV/Sales Ratio Chart
IDXX EV/Sales Ratio Metrics
EV/SALES RATIO
10.38x
EV/SALES RATIO AVG TTM
12.33x
EV/SALES RATIO AVG 3Y
11.50x
EV/SALES RATIO AVG 5Y
11.63x
EV/SALES RATIO AVG 10Y
11.02x
EV/SALES RATIO AVG 15Y
9.03x
EV/SALES RATIO AVG 20Y
7.64x
CURRENT VS TTM AVG
-15.83%
CURRENT VS 3Y AVG
-9.77%
CURRENT VS 5Y AVG
-10.78%
CURRENT VS 10Y AVG
-5.83%
CURRENT VS 15Y AVG
+14.99%
CURRENT VS 20Y AVG
+35.94%
IDXX Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $44.24B | 10.38x | 12.33x | 11.50x | 11.63x |
| Humana Inc. (HUM)vs › | $45.53B | 0.40x | 0.30x | 0.40x | 0.54x |
| Agilent Technologies, Inc. (A)vs › | $36.67B | 5.31x | 5.55x | 5.75x | 6.20x |
| Cardinal Health, Inc. (CAH)vs › | $52.43B | 0.23x | 0.21x | 0.16x | 0.14x |
| Becton, Dickinson and Company (BDX)vs › | $52.98B | 2.69x | 2.87x | 3.33x | 3.47x |
| Cencora, Inc. (COR)vs › | $54.80B | 0.20x | 0.21x | 0.19x | 0.17x |
| Zoetis Inc. (ZTS)vs › | $33.36B | 4.30x | 6.69x | 8.77x | 9.89x |
| Centene Corporation (CNC)vs › | $32.19B | 0.14x | 0.11x | 0.20x | 0.29x |
| Medline Inc. (MDLN)vs › | $30.96B | 1.39x | 1.60x | 1.60x | 1.60x |
| IQVIA Holdings Inc. (IQV)vs › | $30.29B | 2.70x | 2.92x | 3.25x | 3.55x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
IDEXX Laboratories, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IDEXX Laboratories, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for IDEXX Laboratories, Inc. (IDXX)?
- The EV/Sales ratio for IDXX stock is 10.38x.
- Is IDEXX Laboratories, Inc.'s EV/Sales ratio high or low?
- IDEXX Laboratories, Inc.'s EV/Sales ratio of 10.38x is 16% below its 5-year average of 12.37x, near the low end of its 5-year range (7.83x–21.64x).
- What is the TTM average EV/Sales ratio for IDEXX Laboratories, Inc. (IDXX)?
- The TTM average EV/Sales ratio for IDXX stock is 12.33x.
- What is the 3Y average EV/Sales ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 3Y average EV/Sales ratio for IDXX stock is 11.50x.
- What is the 5Y average EV/Sales ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 5Y average EV/Sales ratio for IDXX stock is 11.63x.
- What is the 10Y average EV/Sales ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 10Y average EV/Sales ratio for IDXX stock is 11.02x.
- What is the 15Y average EV/Sales ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 15Y average EV/Sales ratio for IDXX stock is 9.03x.
- What is the 20Y average EV/Sales ratio for IDEXX Laboratories, Inc. (IDXX)?
- The 20Y average EV/Sales ratio for IDXX stock is 7.64x.
IDEXX Laboratories, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-12 | 10.38x |
| 2026-06-11 | 10.33x |
| 2026-06-10 | 10.31x |
| 2026-06-09 | 10.71x |
| 2026-06-08 | 10.39x |
| 2026-06-05 | 10.40x |
| 2026-06-04 | 10.45x |
| 2026-06-03 | 10.38x |
| 2026-06-02 | 10.20x |
| 2026-06-01 | 10.49x |
| 2026-05-29 | 10.43x |
| 2026-05-28 | 10.51x |
| 2026-05-27 | 10.20x |
| 2026-05-26 | 10.31x |
| 2026-05-22 | 10.35x |
| 2026-05-21 | 10.24x |
| 2026-05-20 | 10.25x |
| 2026-05-19 | 10.12x |
| 2026-05-18 | 10.11x |
| 2026-05-15 | 9.80x |
| 2026-05-14 | 9.87x |
| 2026-05-13 | 9.80x |
| 2026-05-12 | 9.89x |
| 2026-05-11 | 9.86x |
| 2026-05-08 | 10.37x |
| 2026-05-07 | 10.59x |
| 2026-05-06 | 10.71x |
| 2026-05-05 | 10.42x |
| 2026-05-04 | 10.76x |
| 2026-05-01 | 10.85x |
| 2026-04-30 | 10.72x |
| 2026-04-29 | 10.59x |
| 2026-04-28 | 10.86x |
| 2026-04-27 | 10.99x |
| 2026-04-24 | 10.82x |
| 2026-04-23 | 10.72x |
| 2026-04-22 | 11.05x |
| 2026-04-21 | 10.87x |
| 2026-04-20 | 11.14x |
| 2026-04-17 | 11.25x |
| 2026-04-16 | 10.89x |
| 2026-04-15 | 11.10x |
| 2026-04-14 | 11.16x |
| 2026-04-13 | 10.97x |
| 2026-04-10 | 10.76x |
| 2026-04-09 | 11.17x |
| 2026-04-08 | 11.30x |
| 2026-04-07 | 10.98x |
| 2026-04-06 | 11.03x |
| 2026-04-02 | 10.88x |
| 2026-04-01 | 10.79x |
| 2026-03-31 | 10.74x |
| 2026-03-30 | 10.65x |
| 2026-03-27 | 10.67x |
| 2026-03-26 | 10.96x |
| 2026-03-25 | 11.00x |
| 2026-03-24 | 10.90x |
| 2026-03-23 | 11.05x |
| 2026-03-20 | 11.03x |
| 2026-03-19 | 11.08x |
| 2026-03-18 | 11.03x |
| 2026-03-17 | 11.21x |
| 2026-03-16 | 11.20x |
| 2026-03-13 | 10.96x |
| 2026-03-12 | 10.92x |
| 2026-03-11 | 11.47x |
| 2026-03-10 | 11.43x |
| 2026-03-09 | 11.65x |
| 2026-03-06 | 11.61x |
| 2026-03-05 | 11.81x |
| 2026-03-04 | 12.37x |
| 2026-03-03 | 12.12x |
| 2026-03-02 | 12.14x |
| 2026-02-27 | 12.52x |
| 2026-02-26 | 12.59x |
| 2026-02-25 | 12.53x |
| 2026-02-24 | 12.38x |
| 2026-02-23 | 11.89x |
| 2026-02-20 | 12.12x |
| 2026-02-19 | 12.43x |
| 2026-02-18 | 12.51x |
| 2026-02-17 | 12.34x |
| 2026-02-13 | 12.40x |
| 2026-02-12 | 12.17x |
| 2026-02-11 | 12.78x |
| 2026-02-10 | 12.73x |
| 2026-02-09 | 12.60x |
| 2026-02-06 | 12.70x |
| 2026-02-05 | 12.68x |
| 2026-02-04 | 12.66x |
| 2026-02-03 | 12.46x |
| 2026-02-02 | 12.60x |
| 2026-01-30 | 13.20x |
| 2026-01-29 | 13.32x |
| 2026-01-28 | 13.53x |
| 2026-01-27 | 13.67x |
| 2026-01-26 | 13.73x |
| 2026-01-23 | 13.65x |
| 2026-01-22 | 13.59x |
| 2026-01-21 | 13.70x |
| 2026-01-20 | 13.50x |
| 2026-01-16 | 14.07x |
| 2026-01-15 | 14.00x |
| 2026-01-14 | 13.97x |
| 2026-01-13 | 14.04x |
| 2026-01-12 | 14.25x |
| 2026-01-09 | 14.03x |
| 2026-01-08 | 14.01x |
| 2026-01-07 | 14.05x |
| 2026-01-06 | 13.90x |
| 2026-01-05 | 13.42x |
| 2026-01-02 | 13.19x |
| 2025-12-31 | 13.31x |
| 2025-12-30 | 13.43x |
| 2025-12-29 | 13.53x |
| 2025-12-26 | 13.55x |
| 2025-12-24 | 13.54x |
| 2025-12-23 | 13.43x |
| 2025-12-22 | 13.81x |
| 2025-12-19 | 13.77x |
| 2025-12-18 | 13.71x |
| 2025-12-17 | 13.68x |
| 2025-12-16 | 13.64x |
| 2025-12-15 | 13.78x |
| 2025-12-12 | 13.85x |
| 2025-12-11 | 13.91x |
| 2025-12-10 | 13.80x |
| 2025-12-09 | 13.75x |
| 2025-12-08 | 13.90x |
| 2025-12-05 | 14.04x |
| 2025-12-04 | 14.11x |
| 2025-12-03 | 14.27x |
| 2025-12-02 | 14.40x |
| 2025-12-01 | 14.33x |
| 2025-11-28 | 14.79x |
| 2025-11-26 | 14.85x |
| 2025-11-25 | 15.06x |
| 2025-11-24 | 14.78x |
| 2025-11-21 | 14.27x |
| 2025-11-20 | 13.56x |
| 2025-11-19 | 13.71x |
| 2025-11-18 | 13.19x |
| 2025-11-17 | 13.17x |
| 2025-11-14 | 13.57x |
| 2025-11-13 | 13.80x |
| 2025-11-12 | 14.03x |
| 2025-11-11 | 14.01x |
| 2025-11-10 | 13.95x |
| 2025-11-07 | 13.93x |
| 2025-11-06 | 14.03x |
| 2025-11-05 | 14.16x |
| 2025-11-04 | 14.20x |
| 2025-11-03 | 14.21x |
| 2025-10-31 | 12.89x |
| 2025-10-30 | 12.87x |
| 2025-10-29 | 12.86x |
| 2025-10-28 | 12.99x |
| 2025-10-27 | 13.25x |
| 2025-10-24 | 13.12x |
| 2025-10-23 | 13.08x |
| 2025-10-22 | 12.98x |
| 2025-10-21 | 13.05x |
| 2025-10-20 | 13.17x |
| 2025-10-17 | 13.01x |
| 2025-10-16 | 13.05x |
| 2025-10-15 | 13.09x |
| 2025-10-14 | 13.04x |
| 2025-10-13 | 12.97x |
| 2025-10-10 | 12.63x |
| 2025-10-09 | 12.88x |
| 2025-10-08 | 12.90x |
| 2025-10-07 | 12.85x |
| 2025-10-06 | 12.86x |
| 2025-10-03 | 12.93x |
| 2025-10-02 | 12.98x |
| 2025-10-01 | 12.70x |
| 2025-09-30 | 13.08x |
| 2025-09-29 | 12.91x |
| 2025-09-26 | 12.95x |
| 2025-09-25 | 12.67x |
| 2025-09-24 | 12.85x |
| 2025-09-23 | 13.27x |
| 2025-09-22 | 13.19x |
| 2025-09-19 | 13.43x |
| 2025-09-18 | 13.41x |
| 2025-09-17 | 13.12x |
| 2025-09-16 | 13.22x |
| 2025-09-15 | 13.18x |
| 2025-09-12 | 13.13x |
| 2025-09-11 | 13.21x |
| 2025-09-10 | 13.06x |
| 2025-09-09 | 13.42x |
| 2025-09-08 | 13.36x |
| 2025-09-05 | 13.16x |
| 2025-09-04 | 13.11x |
| 2025-09-03 | 12.98x |
| 2025-09-02 | 13.09x |
| 2025-08-29 | 13.25x |
| 2025-08-28 | 13.24x |
| 2025-08-27 | 13.12x |
| 2025-08-26 | 13.14x |
| 2025-08-25 | 13.13x |
| 2025-08-22 | 13.21x |
| 2025-08-21 | 12.96x |
| 2025-08-20 | 13.10x |
| 2025-08-19 | 13.04x |
| 2025-08-18 | 13.06x |
| 2025-08-15 | 13.32x |
| 2025-08-14 | 13.38x |
| 2025-08-13 | 13.58x |
| 2025-08-12 | 13.35x |
| 2025-08-11 | 13.35x |
| 2025-08-08 | 13.47x |
| 2025-08-07 | 13.31x |
| 2025-08-06 | 12.79x |
| 2025-08-05 | 13.14x |
| 2025-08-04 | 13.96x |
| 2025-08-01 | 11.39x |
| 2025-07-31 | 11.36x |
| 2025-07-30 | 12.15x |
| 2025-07-29 | 12.17x |
| 2025-07-28 | 12.03x |
| 2025-07-25 | 12.00x |
| 2025-07-24 | 11.69x |
| 2025-07-23 | 11.49x |
| 2025-07-22 | 11.31x |
| 2025-07-21 | 11.08x |
| 2025-07-18 | 10.95x |
| 2025-07-17 | 11.04x |
| 2025-07-16 | 11.07x |
| 2025-07-15 | 11.20x |
| 2025-07-14 | 11.30x |
| 2025-07-11 | 11.34x |
| 2025-07-10 | 11.50x |
| 2025-07-09 | 11.49x |
| 2025-07-08 | 11.45x |
| 2025-07-07 | 11.59x |
| 2025-07-03 | 11.62x |
| 2025-07-02 | 11.54x |
| 2025-07-01 | 11.53x |
| 2025-06-30 | 11.40x |
| 2025-06-27 | 11.30x |
| 2025-06-26 | 11.22x |
| 2025-06-25 | 11.28x |
| 2025-06-24 | 11.28x |
| 2025-06-23 | 11.16x |
| 2025-06-20 | 11.14x |
| 2025-06-18 | 11.06x |
| 2025-06-17 | 11.07x |
| 2025-06-16 | 11.24x |
| 2025-06-13 | 11.12x |
| 2025-06-12 | 11.21x |
| 2025-06-11 | 11.15x |
| 2025-06-10 | 11.19x |
| 2025-06-09 | 11.03x |
| 2025-06-06 | 11.16x |
| 2025-06-05 | 11.11x |
| 2025-06-04 | 11.16x |
| 2025-06-03 | 11.18x |
| 2025-06-02 | 10.95x |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jonathan J. Mazelsky